Repurposing already approved drugs for treating cancers harboring p53 mutations is a promising approach since the (sufficient) safety of these drugs has already been proven and drug repositioning might lead to shorter development times due to the reduced number of required preclinical/clinical testing. This evidence concerns the gene TP53 and cancer.